Alvogen and Lotus Announce First to Launch Generic Version of Navelbin…

Alvogen today announced that its subsidiary Lotus Pharmaceuticals has launched Vinorelbine 20, 30 and 80mg soft capsules in Europe. The product is the generic version of Pierre Fabre M?dicament’s Navelbine®, which is indicated for the treatment of advanced non-small-cell lung cancer (NSCLC) and advanced breast cancer. The product is the first launch of a generic version of Navelbine® in Europe. Alvogen and its business partners are first to market with Vinorelbine softgel capsules in Eur...